Cromolyn and nedocromil therapy of asthmatic children.
Controlled studies of cromolyn treatment of asthmatic children have revealed benefits beyond the incredible safety of the drug. It is now recognized that the patient with asthma will have decreased asthma and less bronchial hyperreactivity when treated for more than two months with cromolyn. Also, the reduced sensitivity of beta-receptors with chronic use of beta adrenergic drugs is abated with concomitant cromolyn use. It is hoped that the studies with nedocromil will reveal additional benefits with this class of antiasthmatic medication.
Furukawa
C T
CT
University of Washington, School of Medicine, Seattle.
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D017835:Nedocromil; D015363:Quinolones / Q000627:therapeutic use*; D011897:Random Allocation; D013806:Theophylline / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015363:Quinolones; D017835:Nedocromil; D013806:Theophylline; D004205:Cromolyn Sodium